secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001178913-22-004019
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab appoints Matthew Frankel as CMO & VP Drug Development, effective Nov 14
--------------------------------------------------------------------------------

- Dr. Frankel will receive annual base salary of $450,000 and bonus potential of 45% of base.
- He receives a signing bonus of $200,000, payable in two $100,000 installments within 60 and 120 days.
- Granted options to purchase 125,000 ADRs, vesting over four years (25% on first anniversary, remainder monthly).
- Frankel previously led clinical development at Boehringer Ingelheim, Novartis, Sandoz, and Reata Pharmaceuticals.
- Interim CMO Dave Weiner will stay on as Senior Advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-004019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer